Version Française
Logo retour accueil
2014 Capital Increase

Last news

  • Interpretation of Clinical Exome (ICE) Project

    Integragen, Gustave Roussy, INSERM and Sogeti High Tech announce the launch of the Interpretation of Clinical Exome (ICE) Project.

    Read more

  • IntegraGen presents data at 2014 ASCO Meeting

    IntegraGen announced today that it presented data during the American Society of Clinical Oncology’s 2014 Annual Meeting which demonstrates that the oncology biomarker miR-31-3p is predictive of cetuximab effects in wild-type (WT) KRAS metastatic colorectal cancer (mCRC) patients.

    Read more


IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.

Autism Oncology Services
Disclaimers - Mentions légales - Crédits